港股異動 | 多重利好加身 四環醫藥(0460.HK)午後漲幅擴大至超11%
格隆匯1月10日丨四環醫藥(0460.HK)午後漲幅擴大,現報1.64港元,大漲11.56%,暫成交1億港元,最新市值153億港元。四環醫藥今日午間宣佈,集團旗下渼顏空間生物科技(吉林)有限公司所研發的醫用皮膚護理凝膠及醫用皮膚修復凝膠獲得中國國家藥監局頒發的醫療器械註冊證。公司表示,此次醫用皮膚護理凝膠及醫用皮膚修復凝膠兩款產品獲批,不僅標誌着集團醫美產品自研管線的進一步落地,而且豐富和擴大了集團醫美平台的產品組合。此外,四環醫藥今日早間亦發公吿稱,與韓國VIOL就黃金微針達成獨家代理協議;另外,抗血栓藥替格瑞洛片(60毫克及90毫克)獲藥品註冊批件。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.